Molecular defects in the mannose binding lectin pathway in dermatological disease: Case report and literature review.

Christopher Miller, Sara Wilgenbusch, Mini Michaels, David S Chi, George Youngberg, Guha Krishnaswamy
Author Information
  1. Christopher Miller: Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA. krishnas@etsu.edu.

Abstract

Mannose-binding lectin (MBL) and the Mannose-binding lectin-associated serine proteases (MASPs) are an essential aspect of innate immune responses that probably play an important but understudied role in cutaneous function. The MBL-MASP pathway appears to exert its primary role by assisting in the clearance of apoptotic skin cells (thus preventing accumulation and a subsequent autoimmune response) and promoting opsonophagocytosis of invading pathogens, limiting their dissemination. Deficiencies of the pathway have been described and are associated with infectious, autoimmune and vascular complications. However, the role of this pathway in dermatological disease is essentially unexplored. We describe 6 patients presenting with recurrent inflammatory and/or infectious skin conditions who also demonstrated severely low MBL levels. One patient also had a defect in the MASP2 gene. Genotype analysis revealed specific point mutations in the MBL2 promoter in all 6 patients and a variant MASP-2 gene in one patient. Five patients presented recurrent pustular skin infections (cellulitis, folliculitis and cutaneous abscess). A case of Grover's disease and one forme fruste of Behcet's syndrome (orogenital ulcers) were also observed. The patients responded to antimicrobial therapy, although in some, recurrence of infection was the rule. It appears that MBL deficiency may contribute to recurrent skin infections and to certain forms of inflammatory skin disease. The mechanisms may relate to the role of this pathway in innate immunity, removal of apoptotic cells and in immune complexes. Further study of MBL pathway defects in dermatological disease is required.

References

  1. Mycopathologia. 2008 Nov-Dec;166(5-6):277-83 [PMID: 18478362]
  2. J Immunol. 2008 Mar 15;180(6):4124-32 [PMID: 18322223]
  3. J Biol Chem. 1994 Jun 3;269(22):15512-9 [PMID: 8195195]
  4. Arch Otolaryngol Head Neck Surg. 2006 May;132(5):482-6 [PMID: 16702562]
  5. Structure. 1994 Dec 15;2(12):1227-40 [PMID: 7704532]
  6. J Immunol. 1998 Sep 15;161(6):3169-75 [PMID: 9743385]
  7. Clin Infect Dis. 2008 Aug 15;47(4):510-6 [PMID: 18611155]
  8. J Invest Dermatol. 2005 Jul;125(1):166-73 [PMID: 15982317]
  9. Arch Dermatol Res. 1989;281(4):279-83 [PMID: 2774659]
  10. Nat Struct Biol. 1994 Nov;1(11):789-94 [PMID: 7634089]
  11. Mol Immunol. 2007 Jan;44(1-3):33-43 [PMID: 16908067]
  12. J Rheumatol. 2005 Feb;32(2):287-91 [PMID: 15693089]
  13. Curr Stem Cell Res Ther. 2008 May;3(2):85-7 [PMID: 18473874]
  14. J Lab Clin Med. 2004 Jun;143(6):358-65 [PMID: 15192652]
  15. J Am Acad Dermatol. 1993 May;28(5 Pt 1):S12-S18 [PMID: 8496405]
  16. J Immunol. 1999 Aug 1;163(3):1498-505 [PMID: 10415052]
  17. J Allergy Clin Immunol. 1993 Jan;91(1 Pt 1):110-9 [PMID: 8423268]
  18. Clin Exp Rheumatol. 2001 Sep-Oct;19(5 Suppl 24):S6-12 [PMID: 11760403]
  19. Nat Genet. 1998 May;19(1):56-9 [PMID: 9590289]
  20. Clin Chem. 2007 Jan;53(1):124-30 [PMID: 17110469]
  21. Genet Epidemiol. 2007 Jan;31(1):31-41 [PMID: 17096357]
  22. Biochem Soc Trans. 2003 Aug;31(Pt 4):774-5 [PMID: 12887302]
  23. J Exp Med. 2004 May 17;199(10):1391-9 [PMID: 15148337]
  24. Clin Exp Rheumatol. 2005 Jul-Aug;23(4 Suppl 38):S96-105 [PMID: 16273774]
  25. Int Immunol. 2007 Feb;19(2):141-9 [PMID: 17182967]
  26. Pediatr Allergy Immunol. 2007 Dec;18(8):665-70 [PMID: 17651383]
  27. Hum Immunol. 1998 Apr;59(4):250-5 [PMID: 9568801]
  28. J Allergy Clin Immunol. 2006 Jul;118(1):202-8 [PMID: 16815156]
  29. J Invest Dermatol. 2007 Jun;127(6):1524-31 [PMID: 17363917]
  30. N Engl J Med. 2004 Jul 15;351(3):260-7 [PMID: 15254284]
  31. Lancet. 1989 Nov 25;2(8674):1236-9 [PMID: 2573758]
  32. Australas J Dermatol. 2004 May;45(2):83-6; quiz 87-8 [PMID: 15068451]
  33. J Exp Med. 2004 May 17;199(10):1379-90 [PMID: 15148336]
  34. N Engl J Med. 2003 Aug 7;349(6):554-60 [PMID: 12904520]
  35. Infect Immun. 2005 Feb;73(2):1052-60 [PMID: 15664949]
  36. Crit Care. 2005 Oct 5;9(5):R483-9 [PMID: 16277709]
  37. Immunobiology. 2007;212(4-5):301-11 [PMID: 17544815]
  38. J Biochem. 1989 Sep;106(3):483-9 [PMID: 2691503]
  39. J Infect Dis. 2004 Aug 1;190(3):632-40 [PMID: 15243942]
  40. J Immunol. 2002 Oct 15;169(8):4430-6 [PMID: 12370377]
  41. Adv Dermatol. 1987;2:305-20 [PMID: 3079260]
  42. Nat Rev Immunol. 2004 Mar;4(3):211-22 [PMID: 15039758]
  43. J Immunol Methods. 2000 Jul 31;241(1-2):33-42 [PMID: 10915847]
  44. Chest. 2004 Jul;126(1):95-9 [PMID: 15249448]

Word Cloud

Created with Highcharts 10.0.0pathwayskinMBLrolediseasepatientsdermatologicalrecurrentalsoMannose-bindinglectininnateimmunecutaneousappearsapoptoticcellsautoimmuneinfectious6inflammatorypatientgeneoneinfectionsmaydefectslectin-associatedserineproteasesMASPsessentialaspectresponsesprobablyplayimportantunderstudiedfunctionMBL-MASPexertprimaryassistingclearancethuspreventingaccumulationsubsequentresponsepromotingopsonophagocytosisinvadingpathogenslimitingdisseminationDeficienciesdescribedassociatedvascularcomplicationsHoweveressentiallyunexploreddescribepresentingand/orconditionsdemonstratedseverelylowlevelsOnedefectMASP2GenotypeanalysisrevealedspecificpointmutationsMBL2promotervariantMASP-2FivepresentedpustularcellulitisfolliculitisabscesscaseGrover'sformefrusteBehcet'ssyndromeorogenitalulcersobservedrespondedantimicrobialtherapyalthoughrecurrenceinfectionruledeficiencycontributecertainformsmechanismsrelateimmunityremovalcomplexesstudyrequiredMolecularmannosebindingdisease:Casereportliteraturereview

Similar Articles

Cited By